[Mexidol in treatment of children with generalized epilepsy and febrile seizures].
The aim of our study was to estimate the role of Mexidol in ceasing of epileptic fits and improving electroencephalographic (EEG) pathological patterns in children. 120 patients with generalized epilepsy (from 4 to 16 years old) were investigated. All patients were treated by Depakin chrono 30 mg/kg. Children were divided into 2 groups: 1st--study group consisted of 60 children with combined treatment with Depakin and Mexidol (5 mg/kg). In the control group (60 children) treatment was performed only by Depakin. 100 children with the first episode of febrile seizures (from 6 months to 4 years old) were investigated. 50 children composed the study group with monotheraphy by Mexidol and 50 patients--the control group, without any treatment. The EEG examination was done by computer EEG Topography "Brain Surveyor Saico". Using Depakin in combination with Mexidol in the study group of patients with generalized epilepsy, improvement of clinical picture of disease and normalization of EEG patterns in 93% of cases has been observed. In the study group of patients with febrile seizures, normalization of EEG pathological patterns was observed in 82% cases and in 18% its improvement was seen. The relapse of seizures at high temperature was observed in 3 patients. In control group EEG patterns were improved only in 20%, in 48% no positive effect was observed and in 41% the worsening of EEG findings was seen. The relapse of febrile seizures was observed in 26 cases. Mexidol titrated to the target doze of 5mg/kg may be effective in combination with Depakin for treatment of patients with generalized epilepsy and as monotherapy in patients with first episode of febrile seizures.
Natriashvili
G
G
Pediatric Clinic, Tbilisi State Medical University, Georgia.
Natriashvili
S
S
Kapanadze
N
N
D000293:Adolescent; D000927:Anticonvulsants / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects; D004829:Epilepsy, Generalized / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D010847:Picolines / Q000494:pharmacology / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000494:pharmacology / Q000627:therapeutic use*; D003294:Seizures, Febrile / Q000150:complications / Q000188:drug therapy*; D014635:Valproic Acid / Q000627:therapeutic use
D000927:Anticonvulsants; D010847:Picolines; D011619:Psychotropic Drugs; C070020:emoxypine succinate; D014635:Valproic Acid